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Abstract
Background: The incidence of major risk factors of chronic kidney disease (CKD) in the world is on the rise, and it is expected that this in-
cidence and prevalence, particularly in developing countries, will continue to increase. Using data on urinary sediment and microalbuminuria, 
we aimed to estimate the prevalence of CKD in northeast Iran.
Methods: In a cross-sectional study, the prevalence of CKD in a sample of 1557 regionally representative people, aged  18 years, was 
analyzed. CKD was determined based on glomerular ltration rate (GFR) and microalbuminuria.  Life style data, urine and blood samples 
were collected. Urine samples without any proteinuria in the initial dipstick test were checked for qualitative microalbuminuria. If the latter was 
positive, quantitative microalbuminuria was evaluated. 
Results: 1557 subjects with a mean age of 56.76 12.04 years were enrolled in this study. Based on the modication of diet in renal dis-
ease (MDRD) equation, 137 subjects (8.89%) were categorized as CKD stages III-V. Based on urine abnormalities, the prevalence of com-
bined CKD stages I and II was 10.63%, and based on macro- and microalbuminuria it was 14.53%. The prevalence of CKD was signicantly 
associated with sex, age, marital status, education, diabetes mellitus (DM), hypertension (HTN), ischemic heart disease (IHD), waist to hip 
ratio, myocardial infarction (MI), and cerebrovascular accident (CVA). 
Conclusion: CKD and its main risk factors are common and represent a denite health threat in this region of Iran. Using and standardizing 
less expensive screening tests in low resource countries could be a good alternative that may improve the outcome through early detection 
of CKD.
Introduction
The incidence of end-stage renal disease (ESRD) is dramati-cally increasing worldwide.1 Most patients with kidney 
problems visit their physicians in the late stages of the dis-
ease. Progression from mild to moderate kidney disease to ESRD 
may be halted or slowed when kidney damage is detected and ap-
propriate treatment is started during the early stages. Kidney dam-
age is frequently asymptomatic but can be suspected in the pres-
ence of proteinuria, hematuria, or a reduced glomerular ltration 
rate (GFR).2 While previously different criteria such as abnormal 
urine sediment and increased serum creatinine level were used to 
dene chronic kidney disease (CKD), in 2002 the Kidney Disease 
Outcomes Quality Initiative (KDOQI) proposed a classication 
system based on changes in the GFR. In this system albuminuria is 
an essential element in the diagnosis of mild CKD (stages I and 
II).3 According to the Kidney Early Evaluation Program (KEEP 
2.0) in the US, 3% of participants reported a history of kidney 
disease. A total of 18% had hematuria and 13% had pyuria. Micro-
albuminuria was found in 29% of participants.4
Proteinuria of less than 150 mg per liter could not be identi-
ed with routine dipsticks. Therefore, more sensitive tools such 
as urine nephelometry are used to detect microalbuminuria. In 
urine nephelometry, albumin > 30 mg/g are considered abnormal. 
Population-based studies on the prevalence of kidney damage, par-
ticularly in its earlier stages and diagnosed with microalbuminuria, 
are limited in countries other than high-income countries.5–8 This 
is in part related to the difculty of applying quantitative methods 
for the detection of albuminuria in large epidemiological studies in 
low- to middle-income countries like Iran.  
We previously reported the prevalence of moderate to severe 
CKD (stages III-V) based on GFR in Golestan Province.9 In this 
study, we provided data on urinary sediment and microalbumin-
uria and extended our previous observations to milder stages of 
CKD (stages I-II). 
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I. Naja, R. Shakeri, F. Islami, et al.
Materials and Methods
The subject enrollment method has been described in detail in 
our previous report.9 In brief, all men aged 50 to 79 and women 
aged 55 to 79 years who resided in the city of Kalaleh and were 
invited to participate in the double-blind randomized placebo-con-
trolled pilot trial of the effects of xed-dose combination therapy 
(‘polypill’) on cardiovascular risk factors in Kalaleh (n = 1488; 
participation rate 70%),10 regardless of their eligibility for the trial, 
were enrolled in this study. To have representative samples of the 
adult population, the study participants were contacted by phone 
and all individuals aged 18 years or older in their household were 
invited to participate (participation rate > 95%). We recruited a to-
tal of 3613 subjects from April 2007 to January 2009. Question-
naire data, and urine, and blood samples were collected from all 
participants. For this study we used data of rst 1557 subjects, 
for whorn microalbuminuria data were available along with urine 
sediment. For the rest of the study quantitative microalbuminuria 
kit was not available due to sanctions on Iran. 
 The study protocol and the informed consent were approved by 
the “Ethics Review Committee” of the “Digestive Disease Re-
search Center” of “Tehran University of Medical Sciences”. Writ-
ten informed consent was obtained from all participants. 
Demographic data, habits, and history of medical conditions in-
cluding diabetes mellitus (DM), hypertension (HTN), ischemic 
heart disease (IHD), and myocardial infarction (MI) were collected 
by face-to-face interviews using a structured questionnaire. Weight 
and height were measured. Systolic and diastolic blood pressures 
were obtained twice within a 20 minute interval for both arms dur-
ing the interview, however, only measurements of the right arm 
were considered for further analyses. Trained physicians conduct-
ed the interviews and physical examinations.
Waist circumference was measured at the umbilical level as well 
as hip circumference at the maximal level over light clothing. 
Waist to hip ratio was calculated by dividing waist to hip circum-
ference. Weight was recorded using scales (with precision of up to 
50 g). Height was measured using a tape stadiometer. Body mass 
index (BMI) was calculated by dividing weight (in kg) by squared 
values of height (in meters). In order to reduce inter-observer vari-
ability, only one of the research team members performed all the 
anthropometric measurements.
Fasting blood samples and one-spot urine samples were collected 
from all participants. Blood samples were drawn by a nurse, after 
at least ten hours of overnight fasting. Serum was separated and 
kept in 70°C freezers in the study center for a maximum period of 
three months.  The samples were transported in dry ice to a refer-
ence laboratory where biochemical analysis was performed.  The 
laboratory analyses were done within a few days after arrival with 
endpoint enzymatic photometric method using a Hitachi 902 auto-
analyzer. 
Fasting blood glucose was measured by the glucose oxidase 
method (Pars Azmon Inc., Iran) with an inter-assay coefcient of 
variation (CV) of 3% and an intra-assay CV of 0.8%. Total choles-
terol (TC) and triglyceride (TG) levels were measured using enzy-
matic colorimetric kits (Pars Azmon, Inc.) with an inter-assay CV 
of 2% and an intra-assay CV of 0.5% for TC, an inter-assay CV 
Characteristic Number (%) Characteristic Number (%)
All participants 1557 (100) Marital Status
Women 829 (53.24) Married 1330 (85.42)
Men 728 (46.76) Single 44 (2.83)
Age (years) Widowed/divorced 183 (11.75)
< 30 82 (5.27) Education
30–39 62 (3.98) No school 935 (60.05)
40–49 86 (5.52) Primary school 350 (22.4)
50–59 672 (43.16) Middle school 69 (4.4)
60–69 435 (27.94) High school 139 (8.9)
 70 220 (14.13) University 64 (4.1)
Ethnicity BMI
Sistani 583 (37.44) < 18.5 57 (3.66)
Turkmen 409 (26.27) 18.5–24.9 1103 (70.8)
Fars 347 (22.29) 25–29.9 331 (19.9)
Other 218 (14.00)  30 86 (5.5)
Hypertension Diabetes 
Self-reported 393 (25.2) Self-reported 239 (15.3)
Sys  140 or Dias  90 mmHg 673 (43.2) FBS  110 mg/dL 328 (21.07)
Any criteria 792 (50.8) Any criteria 414 (26.6)
Ischemic heart disease 177 (11.3) Myocardial infarction 49 (3.1)
Table 1.  Distribution of demographic variables, BMI, and medical history among groups of interest.
All participants Total no. Mean age (SD) GFR < 15 GFR: 15–29 GFR: 30–59 GFR: 60–89 GFR  90
Women 1542 56.76 (12.04) 4 (.26) 4 (.26)) 129 (8.37) 1043 (67.64) 362 (23.48)
Men 821 58.08 (10.53) 4 (0.49) 2 (0.24) 47 (5.72) 540 (65.77) 228 (27.77)
Age (years) 721 55.25 (13.4) 0 (0.0) 2 (0.28) 82 (11.37) 503 (69.76) 134 (18.59)
<30 81 23.1 (3.5) 0 (0.0) 0 (0.0) 1 (1.23) 17 (20.99) 63 (77.78)
30–39 62 34.22 (2.8) 0 (0.0) 0 (0.0) 2 (3.23) 46 (74.19) 14 (22.58)
40–49 86 5 (3.1) 0 (0.0) 0 (0.0) 1 (1.16) 69 (80.23) 16 (18.60)
50–59 666 54.67 (2.79) 1 (0.15) 2 (0.3) 20 (3.00) 480 (72.07) 163 (24.47)
60–69 432 63.7 (3.0) 1 (0.23) 2 (0.46) 62 (14.35) 283 (65.51) 84 (19.4)
 70 220 72.4 (2.41) 2 (0.93) 0 (0.0) 43 (20.0) 148 (68.84) 22 (10.23)
BMI = body mass index (kg/m2); GFR = glomerular ltration rate (ml/min/1.73 m2); MDRD = Modication of Diet  in Renal Disease; SD = standard deviation. 
Values are numbers (percentages) of participants unless stated otherwise.
Table 2.  MDRD-based glomerular ltration rate by sex and age.
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of 1.6% and an intra-assay CV of 0.6% for TG. Serum creatinine 
levels were assessed according to the standard colorimetric Jaffe-
Kinetic reaction method (Pars Azmon Inc., Iran), with an inter-
assay CV of 2.5%, an intra-assay CV of 1.9%, and a sensitivity of 
0.2 mg/dL. The assay range was 18–1330 mol (0.2–15 mg/dL). 
Assay performance was monitored after every 30 tests using the 
control serum, TrueLab N (Lot. no. 11382; Pars Azmon, Inc., Iran) 
for normal ranges and TrueLab P (Lot. no. 11383; Pars Azmon, 
Inc., Iran) for pathological ranges. In subjects with abnormal urine 
sediment and creatinine levels, these parameters were rechecked 
after at least three months.
Urine samples were sent to a local reference laboratory the morn-
ing of collection. When samples showed abnormal urine ndings 
(white blood cells > 5 or red blood cells > 3 per high-power eld, 
or protein  trace), a visit to a nephrologist and complementary 
tests including urine culture, renal ultrasound, and additional tests 
(depending on ndings) were considered. Protein/creatinine ratio 
was calculated for samples with proteinuria. For samples with no 
urine sediment abnormality, the presence of microalbuminuria was 
qualitatively examined and if the test was positive, albumin was 
then measured quantitatively using the nephelometric method. 
Because of the sanctions against Iran and the unavailability of 
Variable
CKD stages 
I-V (%)
n = 361
GFR 90 (%)
n = 1181
Crude OR
(95% CI) Variable
CKD stages 
I-V (%)
n = 361
GFR 90 
(%)
n = 1181
Crude OR
(95% CI)
Sex Diabetes
Women 190 (52.6 650 (55.04) Reference Self-reported 95 (26.3) 143 (12.1) 2.59 (1.93–3.47)
Men 171 (47.3) 531 (44.96) 0.73 (0.58–0.93) FBS 110 mg/dL 126 (34.9) 202 (17.1) 2.59 (1.99–3.38)
Age (years) Any criteria 145 (40.2) 268 (22.7) 2.28 (1.77–2.93)
< 30 11 (3.05) 70 (5.93) Reference Waist to hip ratio
30–39 8 (2.22) 54 (87.10) 0.94 (.35–2.50) Below25% 
quartile
75 (20.78) 309 (26.16) Reference
40–49 12 (13.95) 74 (6.27) 1.03 (0.42–2.49) 25–50% quartile 84 (23.27) 303 (25.66) 1.14 (0.80–1.61)
50–59 113 (31.30) 553 (46.82) 1.30 (0.66–2.53) 50–75% 
quartile
97 (26.87) 318 (26.93) 1.25 (0.89–1.76)
60–69 133 (36.84) 299 (25.32) 2.83 (1.45–5.51)         Above75%
        quartile 105 (29.09) 251 (21.25) 1.72 (1.22–2.42)
 70 84 (23.27) 131 (11.09) 4.08 (2.04–8.15) IHD 64 (17.73) 112 (9.48) 2.05 (1.47–2.86)
Ethnicity BMI
Sistani 122 (33.8) 454 (38.4) Reference <18.5 7 (2) 47 (4) 0.52 (0.23–1.18)
Turkmen 91 (25.2) 315 (26.7) 1.07 (0.79–1.46) 18.5-24.9 250 (69.2) 844 (71.5) Reference
Fars 93 (25.8) 250 (21.2) 1.38 (1.01–1.88) 25-29.9 86 (23.8) 222 (11.8) 1.07 (0.81–1.42)
Others 55 (15.2) 162 (13.7) 1.26 (0.87–1.82)  30 18 (5) 68 (5.7) 1.25 (0.92–1.70)
Marital  status HTN
Married 296 (82.0) 1021 (86.5) Reference Self-reported 146 (40.44) 245 (20.75) 2.59 (2.01–3.34)
Widowed
/Divorced
61 (16.9) 122 (10.3) 1.7 (1.23–2.40) Sys 140 or Dias 90 
mmHg
208 (57.62) 459 (38.87) 2.06 (1.01–4.18)
Single 4 (1.1) 38 (3.2) 0.36 (0.12–1.02) Any criteria 237 (65.65) 547 (46.32) 2.21 (1.73–2.83)
Education MI 18 (4.99) 31 (2.62) 1.94 (1.07–3.52)
No school 229 (63.4) 695 (58.8) Reference CVA 14 (3.88) 23 (1.95) 2.14 (1.33–3.46)
Primary school 85 (23.5) 262 (22.2) 0.35 (0.23–0.57) Smoking 50 (13.85) 191 (16.17) 0.83 (0.59–1.16)
Middle school 16 (4.4) 53 (4.5) 0.11 (0.05–0.23) Opium 46 (12.74) 161 (13.63) .92 (0.65–1.31)
High school 19 (5.3) 120 (10.2) 0.04 (0.02–0.08) Nass 21 (5.82) 65 (5.50) 1.06 (0.63–1.76)
University 12 (3.3) 51 (4.3) 0.05 (0.02–0.14) Alcohol 1 (0.28) 9 (0.76) 0.36 (0.04–2.86)
Table 3. Univariate analysis of effect of variables on CKD.
Variable
CKD positive
n = 361
CKD negative
n = 1181 P-value for student t-test
Mean (SD) Mean (SD)
Uric acid 5.23 (1.54) 5.22 (7.39) 0.97
Cholesterol 198.96 (50.84) 190.21 (53.38) 0.005
Triglyceride 163.02 (100.13) 147.59 (108.66) 0.01
HDL 45.65 (12.30) 47.38 (13.30) 0.02
LDL 115.30 (33.95) 108.58 (42.79) 0.006
ESR 19.74 (14.17) 14.03 (9.90) 0.000
HB 12.56 (1.70) 12.67 (1.66) 0.27
FBS 119 (2.82) 102.06 (1.23) 0.0000
Waist to hip ratio 0.95 (0.004) 0.93 (0.002) 0.0016
Table 4. Difference between mean of biochemical factors and waist to hip ratio based on CKD status.
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qualitative microalbuminuria kits, qualitative evaluation of micro-
albuminuria was performed only in the 1557 subjects with normal 
urine sediment ndings. 
Denitions
For this study, GFR was estimated from the abbreviated predic-
tion equation provided by the Modication of “Diet in Renal Dis-
ease (MDRD)” study as follows:
GFR = 186 × (SCr)-1.154 × (Age)-0.203 × (0.742 if female) × 
(1.210 if African-American)
We classied CKD stages I-II through two modalities:
1) Based on macro and microalbuminuria: GFR > 60 mL/min 
per 1.73 m2 and microalbuminuria  30 mg or  trace positive pro-
teinuria. 
2) Based on urine sediment: GFR > 60 mL/min per 1.73 m2 and 
abnormal urine sediment (described above).  
We dened stages III CKD as a GFR of 31–60 mL/min and stage 
IV as a GFR of 16–30 mL/min; and  stage V as a GFR  15 mL/
min per 1.73 m2. 
BMI was categorized in four groups of < 18.5 kg/m2, 18.5 to 
24.9, 25 to 29.9 and  30 kg/m2. Abnormal waist circumference 
was set as  102 cm in men and  88 cm in women according to 
the “Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults”. Opium usage, cigarette smok-
ing, and nass (a chewing tobacco mixture) were dened as being 
used at least once a week for six months. DM was dened accord-
ing to the criteria of the last statement of the “American Diabetes 
Association (ADA)” as fasting plasma glucose  110 mg/dL, in-
cluding patients who had known cases of diabetes and were using 
insulin or oral glucose-lowering agents. 
 We have dened presence or absence of HTN and DM by three 
different ways:
1) Self-reported (data which was obtained by the questionnaire),
2) Measured (data which was obtained through measurement), and 
3) Both 1 and 2.
Classication of measured blood pressure was based on “The 
Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
(JNCVII)”.
Results
Initially there were 1557 enrolled subjects in this study, with a 
mean age of 56.76 ± 12.04 (female: 55.25 ± 13.40 and male: 58.08 
± 10.53 years) who were assumed to be one group of interest. The 
demographic characteristics of these subjects are presented in Ta-
ble 1. 
We calculated the awareness rate of the interest group with afore-
mentioned medical problems by dividing the self-reported num-
bers to the sum of measured and self-reported data. Only 10% of 
patients with kidney disease, 57.6% with diabetes, and 49.8% with 
HTN were aware of their illness.
A family history of HTN was noted in 20.88% of the subjects, 
compared to family history of DM (13%), IHD (5.38%), MI 
(6.87%) and cerebrovascular accident (CVA; 6.74%).  Alcohol 
consumption was rare (0.65%), while 15.63% of the subjects 
smoked cigarettes, 13.42% used opium and 5.58% used nass. 
The distribution of GFR classied groups according to demographic 
and health characteristics are presented in Table 2. Among the study 
population, the mean creatinine level was 0.97 ± 0.51 mg/dL, and the 
mean estimated GFR based on the MDRD formula was 80.2 ± 34.52 
mL/min/1.73 m2. High serum creatinine in men (> 1.3 mg/dL) was 
detected in 36 subjects, and in 48 women (> 1.1 mg/dL).
 Using a logistic regression analysis the prevalence of CKD was 
associated with sex, age, marital status, education, DM, HTN, 
IHD, waist to hip ratio, MI and CVA (Table 3). In multivariate 
analysis, sex, age, DM, HTN, and IHD showed a signicant as-
sociation with CKD. There was a signicant difference between 
mean cholesterol, TG, HDL, LDL, ESR, FBS, and waist to hip 
ratio of CKD patient and healthy subjects (Table 4).
Table 5 shows CKD prevalence using macro- and micro-albu-
minuria versus urine sediment. The GFR measurement based on 
the MDRD equation is used as a universal protocol to categorize 
CKD stages III-V. Based on dipstick and urine analysis, 5.7% 
had proteinuria (5.4% of females, 6% of males), 3.7% had pyuria 
(5.4% of females and 2.3% of males) and 5.5% had hematuria 
(6.6% of females, 4.6% of males). Among individuals with pyuria, 
72% had a positive urine culture but only 35% had a colony count 
more than 100 000 (Table 5).
Based on the MDRD equation a total of 137 subjects (8.89%) 
and based on the Cockroft-Gault a total of 219 subjects (14.2%) 
were categorized as CKD stages III-V. Using the MDRD equation 
with macro- and micro-albuminuria classication, 23.42% (stages: 
I, 3.8%; II, 10.7%; III, 8.37%; IV, 0.26; and V, 0.26%) had CKD. 
With urine sediment, 19.52% (stages: I, 2.2%; II, 8.1%; III, 8.37%; 
IV, 0.26; and V, 0.26%) had CKD.  
During the study, 500 participants (out of 3613) had abnormal 
urine sediment and/or elevated serum creatinine. There were 200 
who had further evaluations by a nephrologist, including repeat-
ing the abnormal test sonography and/or radiography, and on rare 
occasion’s, admission to a hospital. The most prevalent diagnoses 
Different groups 
& different 
screening protocol 
Number of 
participants Mean age (SD)
CKD stages I-II
( GFR > 60 and
albuminuria)
N (%)
CKD stages I-II
( GFR > 60 and
abnormal  
sediment)
N (%)
CKD stages III-V
N (%)
CKD stages I-V
based on abnormal 
sediment
N (%)
Group of interest
( our study group) 1557 56.73 (12.03) 221 (14.53) 164 (10.63) 137 (8.89) 301 (19.52)*
Remainder 2056 34.06 (10.24) ND** 180(8.78) 28 (1.37) 208 (10.15)
Total 3613 43.84 (15.76) ND** 344 (9.57) 165 (4.60) 509 (14.17)
*CKD prevalence in group of interest based on microalbuminuria = 14.53 + 8.89 = 23.42%; **ND = Not done.
Table 5. CKD prevalence using microalbuminuria versus urine sediment.
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between these subjects were Hypertension, diabetes mellitus, obe-
sity and X syndrome. 
Discussion
Due to increased awareness of people about CKD and early 
detection and prevention programs implemented in developed 
countries, the incidence of ESRD has shown a small downward 
trend.11–12 However the total number of individuals worldwide with 
CKD is still high and estimated at 500,000,000 people.
In our study, 4.6% of the population of Kalaleh has stage III-V 
CKD, which was consistent with the result of the NHANES study 
in which a CKD prevalence of 4.7% was reported in the US.13 
However, in different parts of the world this gure varies between 
2.5% in China,6 6.9% in Taiwan,14 7.8% in Congo,15 and 10.9% in 
Australia.2 In a study of over 17000 people from Iran, a prevalence 
of 6% to 17% in different provinces were recorded.16 In the capital 
city of Tehran, the prevalence of CKD stages III-V among 32000 
taxi drivers was found to be 6.5% in men and 13.7% in women.17 
In another study in Tehran, with over ten thousand surveyed, a very 
high number of 19% was noted.18
For the denition of CKD stages I and II, different screening 
protocols (estimated GFR plus macro- and microalbuminuria, and 
abnormal urine sediment) were used. In this study, we compared 
the CKD prevalence among our subjects based on two modali-
ties. Taking into account the macro- and microalbuminuria in our 
evaluation strategy showed us a higher percent of CKD compared 
to using only abnormal urine analysis and GFR measurement 
(19.52% vs. 23.41%). Such an increase in detection of CKD by 
microalbuminuria measurement is an expected nding since the 
latter is the most precise way of determining CKD. Similar to our 
study, analysis of NHANES data from 4101 individuals from 1999 
to 2000 (using dipstick albuminuria) showed a CKD prevalence 
of 1.7% in males and 0.9% in females. These gures rose to 7.3% 
and 10.4% when the quantitative measurement of microalbumin-
uria was used as the modality for CKD determination.19
Though the relation between microalbuminuria to cardiovascular 
and renal morbidity and mortality has been well documented by 
several studies,20–21 we are not aware of studies evaluating a simi-
lar relationship with abnormal urine sediment in CKD patients. In 
concordance with previous reports only 25% (26/104) of our CKD 
stage III had microalbuminuria. The numbers were also similar for 
abnormal urine sediment 28.5% (44/154). The deleterious renal 
and cardiac effect of microalbuminuria is well known. In fact, in 
Multiple Risk Factor intervention and CARE trials20 and the Fram-
ingham Offspring cohort21 it has been documented that regardless 
of the stages of CKD, the main hazard for developing ESRD and 
cardiovascular events comes from albuminuria. We are not aware 
of long-term clinical consequences due to abnormal urine sedi-
ment in CKD, which should be investigated in the future. In our 
study, diabetes, HTN, obesity and metabolic syndrome accounted 
for 70% of the causes of CKD in subjects with abnormal screening 
tests that underwent further evaluation. These gures are similar to 
the results in the US presented in Figure 1. 
In the NHANES study, the prevalence of moderate or severe de-
creased kidney function in the age group  70 years was reported 
to be around 20.6%, which was substantial even in the absence 
of diabetes or HTN (10.8%).13 Accordingly, we found a higher 
percent of CKD among older individuals (age  50 years) than 
younger (age 20–40 years) in this study (23.27% vs. 3.05%).
In the general population of Kalaleh, type two DM had a preva-
lence of 17.5% compared to the worldwide reported gure of 5%. 
The high prevalence of diabetes in Kalaleh could be explained by 
the high rate of BMI > 25 (60%), lack of physical activity, and 
possibly genetic and racial background. In the KEEP study, 27% 
of people with CKD had diabetes, a gure similar to our study. 
However, the prevalence of HTN was much higher in our study 
group compared to KEEP (50% vs.17%), while obesity was lower 
(27% vs. 44%).4 Despite nding an association between CKD and 
several known risk factors that included HTN, DM, IHD, MI, and 
waist to hip ratio, no association existed between CKD and BMI. 
The correlation between CKD and waist to hip ratio and not BMI 
is plausible since this ratio is a more representative marker of meta-
bolic syndrome than BMI.
One interesting nding of our study was the marked difference 
in our subjects’ awareness of their presence or absence of CKD 
compared with diabetes and HTN. This was partly due to the long 
history of successful public education about diabetes and HTN 
compared to renal disease in Iran, as well as the lack of knowledge 
among health care workers regarding the importance of screening 
patients for CKD. 
It is worth noting the limitations and strengths of the current 
study. First, estimating the GFR from the serum creatinine level has 
well-recognized limitations, including substantial variation in cre-
atinine production by age, sex, and race.22 To minimize the impact 
of these limitations, we used the MDRD equation which has an 
increased precision of GFR estimation. As expected, the Cockroft-
Gault equation underestimates GFR, so the prevalence of CKD 
based on this method is higher compared to the MDRD equation. 
Unfortunately, we did not have access to the calibration of serum 
creatinine values or to the laboratory that generated data for the de-
velopment of this equation. Also, microalbuminuria was measured 
only in 40% of participants (n = 1557) due to unavailability of the 
kit in Iran. This resulted in the complete data only in a subgroup 
of participants not representative of the total group, because this 
group was older and had more co-morbidity. The strength of this 
study was that we were able to compare CKD prevalence based on 
two screening methods, macro and microalbuminuria and abnor-
mal urine sediment. We showed that the prevalence of CKD was 
4% higher using the former method.
In this study, we found a similar prevalence of CKD in Kalaleh, 
as well as its main risk factors (age, diabetes, HTN, metabolic syn-
drome, and obesity) compared with developed countries. Simple 
urine analysis plus creatinine measurement are easily available and 
could diagnose the majority of our patients with CKD. Perhaps in 
low resource countries this can be recommended as a minimum for 
screening purposes, and routine use of microalbuminuria be used 
in a high-risk population. 
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